Clinicopathological features of patients with middle third gastric carcinoma

Table 1 Clinicopathologic findings of middle, proximal and distal third gastric carcinoma patients

Variables	MGC (n = 919) (%)	PGC (n = 312) (%)	DGC (n = 2000) (%)	P value
Age (mean, yr)	55.8 ± 11.7	55.8 ± 12.5	57.6 ± 10.7	< 0.001
Gender				0.277
Male	602 (65.5)	219 (70.2)	1327 (66.4)
Female	317 (34.5)	93 (29.8)	673 (33.6)
Tumor size (mean, cm)	4.2 ± 2.8	4.7 ± 2.6	3.7 ± 2.3	< 0.001
Depth of invasion				< 0.001
T1	296 (32.2)	41 (13.1)	648 (32.4)
T2	112 (12.2)	45 (14.4)	307 (15.4)
T3	410 (44.6)	177 (56.8)	844 (42.2)
T4	101 (11.0)	49 (15.7)	201 (10.0)
Histologic type				< 0.001
Differentiated	324 (35.3)	108 (34.6)	941 (47.1)
Undifferentiated	595 (64.7)	204 (65.4)	1059 (52.9)
Lymph node dissection				0.018
< D2	215 (23.4)	51 (16.3)	475 (23.7)
≥ D2	704 (76.6)	261 (83.7)	1525 (76.3)
Lymph node metastasis				0.045
N (-)	561 (61.1)	125 (40.1)	1217 (60.9)
N (+)	358 (38.9)	187 (59.9)	783 (39.1)
Operative type				< 0.001
Total gastrectomy	297 (32.3)	267 (85.6)	75 (3.8)
Others	622 (67.7)	45 (14.4)	1925 (96.2)
Hepatic metastasis				0.068
H (-)	899 (97.8)	300 (96.2)	1914 (95.7)
H (+)	20 (2.2)	12 (3.8)	86 (4.3)
Peritoneal dissemination				0.556
P (-)	838 (91.2)	282 (90.4)	1829 (91.4)
P (+)	81 (8.8)	30 (9.6)	171 (8.6)
Stage				< 0.001
I	356 (38.7)	71 (22.7)	840 (42.0)
II	167 (18.2)	66 (21.2)	322 (16.1)
III	223 (24.3)	109 (34.9)	432 (21.6)
IV	173 (18.8)	66 (21.2)	406 (20.3)
Curability				0.796
Curative	764 (83.1)	254 (81.4)	1658 (82.9)
Non-curative	155 (16.9)	58 (18.6)	342 (17.1)

MGC: Middle third gastric carcinoma; PGC: Proximal third gastric carcinoma; DGC: Distal third gastric carcinoma.

Table 2 Univariate analysis of prognostic factors in middle third gastric carcinoma patients

Variables	No. of patients	5-yr survival rate	P value
Age			0.0057
< 65	688	56.0
≥ 65	231	40.0
Gender			0.0161
Male	602	48.9
Female	317	59.9
Tumor size (cm)			< 0.001
< 5	616	68.5
≥ 5	303	28.0
Depth of invasion			< 0.001
T1	296	88.3
T2	112	75.9
T3	410	37.8
T4	101	15.4
Histologic type			0.0294
Differentiated	324	62.8
Undifferentiated	595	48.2
Hepatic metastasis			< 0.001
(-)	899	53.7
(+)	20	10.8
Operative type			0.4327
Total	297	52.4
Others	622	63.6
Lymph node invasion			< 0.001
N (-)	561	77.5
N (+)	358	32.7
Lymph node dissection			< 0.001
< D2	215	18.3
≥ D2	704	60.0
Stage			< 0.001
I	356	87.5
II	167	62.5
III	223	35.2
IV	173	14.7

Table 3 Influence of T category, and N category on the 5-year survival rate of patients with middle third gastric carcinoma surgically treated with curative intent

Variables	PGC (n = 254) (%)	MGC (n = 764) (%)	P value
Depth of invasion
T1	77.6	88.8	0.0477
T2	76.0	76.1	0.7534
T3	44.6	45.1	0.9900
T4	17.3	16.8	0.1698
Lymph node metastasis
N0	72.3	79.9	0.0270
N1	42.7	49.6	0.6285
N2	33.4	31.0	0.6933
Stage
I	77.2	87.9	0.0420
II	68.4	63.2	0.5566
III	33.7	36.3	0.5823
IV	17.6	21.8	0.3635

MGC: Middle third gastric carcinoma; PGC: Proximal third gastric carcinoma.

Table 4 Multivariate analysis of survival for middle third gastric carcinoma patients

Variables	Risk ratio	95%CI	P value
Age (< 65 vs≥ 65)	1.78	1.24-2.55	0.002
Tumor size (mm) (< 50 vs≥ 50)	1.51	1.03-2.21	0.036
Serosal invasion (negative vs positive)	2.46	1.45-4.15	0.001
Lymph node metastasis (negative vs positive)	2.48	1.59-3.87	0.000
Curability (curative vs non-curative)	3.46	2.29-5.23	< 0.001